###begin article-title 0
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation
###end article-title 0
###begin p 1
###xml 710 713 710 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1218 1221 1218 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1302 1305 1302 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1508 1511 1508 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1578 1581 1578 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1653 1656 1653 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 659 666 <span type="species:ncbi:9606">patient</span>
###xml 736 743 <span type="species:ncbi:9606">patient</span>
###xml 1181 1189 <span type="species:ncbi:9606">patients</span>
###xml 1674 1681 <span type="species:ncbi:9606">patient</span>
The 21-kD protein Ras of the low-molecular-weight GTP-binding (LMWG) family plays an important role in transduction of extracellular signals. Ras functions as a 'molecular switch' in transduction of signals from the membrane receptors of many growth factors, cytokines, and other second messengers to the cell nucleus. Numerous studies have shown that in multiple malignant tumors and hematopoietic malignancies, faulty signal transduction via the Ras pathway plays a key role in tumorigenesis. In this work, a non-radioactive assay was used to quantify Ras activity in hematologic malignancies. Ras activation was measured in six different cell lines and 24 patient samples, and sequence analysis of N- and K-ras was performed. The 24 patient samples comprised of seven acute myelogenous leukemia (AML) samples, five acute lymphocytic leukemia (ALL) samples, four myeloproliferative disease (MPD) samples, four lymphoma samples, four juvenile myelomonocytic leukemia (JMML) samples, and WBC from a healthy donor. The purpose of this study was to compare Ras activity determined by percentage of Ras-GTP with the mutational status of the Ras gene in the hematopoietic cells of the patients. Mutation analysis revealed ras mutations in two of the seven AML samples, one in codon 12 and one in codon 61; ras mutations were also found in two of the four JMML samples, and in one of the four lymphoma samples (codon 12). We found a mean Ras activation of 23.1% in cell lines with known constitutively activating ras mutations, which was significantly different from cell lines with ras wildtype sequence (Ras activation of 4.8%). Two of the five activating ras mutations in the patient samples correlated with increased Ras activation. In the other three samples, Ras was probably activated through "upstream" or "downstream" mechanisms.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00277-008-0593-6) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-ras</italic>
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-ras</italic>
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-ras</italic>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1120 1123 1120 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1130 1131 1130 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1522 1525 1522 1525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1558 1561 1558 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1574 1577 1574 1577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1678 1679 1676 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1681 1682 1679 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1888 1889 1886 1887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1967 1970 1965 1968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 2032 2033 2030 2031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 1806 1814 <span type="species:ncbi:9606">patients</span>
###xml 1941 1949 <span type="species:ncbi:9606">patients</span>
Mutations in the ras proto-oncogenes (H-ras, N-ras, K-ras) are the most common genetic aberrations in human tumors, occurring in 20-30% of all tumors; although this figure varies considerably depending on the tumor entity. The most frequently observed ras mutations occur in codons 12, 13, and 61, with these mutations disrupting the GTPase function of Ras. Although the mutated Ras still forms a complex with regulatory GTPase activating proteins (GAPs), conversion of guanosine-5'-triphosphate (GTP) to guanosine-5'-diphosphate (GDP), i.e., Ras inactivation, is attenuated. This blockade leads to a longer half-life of the active GTP-binding form of Ras. Besides mutations in codons 12, 13, and 61, sporadic mutations have been described in codons 116, 117, 119, and 146. These mutations decrease the protein's affinity towards nucleotides, leading to an exchange in favor of cytosolic GTP, of which there is a ten-fold higher level than GDP. In addition, the binding of hydrolysis-enhancing GAPs is inhibited. Moreover it has been shown that mutations in codons 59 and 63 activate the transforming potential of the H-ras gene [1] but are of little clinical relevance. Hence, all known mutations lead to an accumulation of constitutively active Ras and uninterrupted signal transfer. In malignant hematopoietic diseases, activating Ras mutations occur most commonly in myeloid disorders, in myelodysplastic syndrome (MDS) and AML, with the level of Ras activation ranging from 6 to 37%. The mutations occur largely in N-ras codons 12, 13, and 61, and in K-ras codon 12; H-ras mutations are rarely seen in this entity. The most common mutation is a G-->A mutation in codon 12 [2, 3]. Activated Ras mutations appear to play an important part in the transformation from MDS to AML, and a high percentage of patients with MDS-based AML develop Ras mutations in the course of their disease [4]. Furthermore, a prospective study showed that MDS patients with a confirmed ras mutation have a significantly higher risk of developing AML [5].
###end p 6
###begin p 7
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 509 512 509 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 753 754 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
In addition to mutations in the ras gene, Ras can be activated by constitutively active proto-oncogenes and inactivated by tumor suppressor genes [6]. Several receptor tyrosine kinases and non-receptor tyrosine kinases signal via the Ras transduction pathway. Point mutations in the CSF-1 receptor (c-FMS) are found in 10-20% of all AML and MDS patients [7]. Another common defect in AML and MDS is tandem duplications in the FLT3 receptor, which occur in 20-25% of all AML cases. Simultaneous mutations in N-ras and FLT3 are very rare [8]. Members of the c-Kit/c-FMS receptor kinase family (e.g., c-Kit, c-FMS, FLT3) associate with proteins of the Ras/MAPK signal transduction pathway (e.g., Grb-2 and Shc). Hence, their activation could activate Ras [9].
###end p 7
###begin p 8
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
The Bcr-Abl fusion protein occurs in 95% of chronic myelogenous leukemia (CML) cases and in 10% of ALL cases. Although ras mutations in CML are rare, several experiments have shown that Ras activation via the constitutively active Bcr-Abl protein plays an important role. Inhibition of Ras activity by antisense oligonucleotides, microinjection of a blocking monoclonal antibody, or overexpression of dominant-negative Ras-GAP block transformation by Bcr-Abl [10, 11]. Another Abl fusion protein, Tel-Abl, is found in AML featuring a t(12;9) translocation [12, 13]. Other fusion proteins that activate the Ras/MAPK transduction pathway are: (1) the Npm-Alk fusion protein in anaplastic large cell non-Hodgkin's lymphoma featuring a t(2;5) translocation [14, 15]; and (2) Tel-PDGFR-a fusion protein comprising the transcription factor Tel (translocation, Ets, leukemia) and PDGFR, which occurs in a subpopulation of chronic myelomonocytic leukemia (CMML) and features a t(5;12) translocation [12].
###end p 8
###begin p 9
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 549 552 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 591 594 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 342 350 <span type="species:ncbi:9606">children</span>
A number of tumor repressor genes trigger dysregulation of Ras activity. These include the Ras-GAP NF-1, which is mutated in the autosomal dominant form of neurofibromatosis type 1 [16, 17]. In adolescents, neurofibromatosis type 1 is associated with an increased risk of developing myeloproliferative disorders, particularly JMML. In 15% of children with JMML not showing clinical symptoms of neurofibromatosis, inactivating NF-1 mutations have been found [18]. Furthermore, 15-30% of JMML cases that lack the NF-1 mutation present with activating ras mutations [19]. Mutations in both the ras and NF-1 genes are very rare and seem to be mutually exclusive [20].
###end p 9
###begin p 10
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
Somatic PTPN11 mutations occur in approximately 35% of JMML patients [18, 21-22]. PTPN11 encodes the tyrosine phosphatase SHP-2 which transmits signals of growth factor receptors to Ras and other effectors. Thus, Ras can be activated by either an activating mutation in the ras gene or by mutations in proteins that signal through Ras. Gain-of-function mutations of RAF1, a downstream Ras effector, cause Noonan syndrome in patients who do not have a mutation of Ras or upstream effectors [23, 24].
###end p 10
###begin p 11
###xml 169 177 <span type="species:ncbi:9606">patients</span>
In this study, Ras activity determined by the ratio of Ras-GTP to Ras-GDP has been compared with the mutational status of the Ras gene in the hematopoietic cells of the patients.
###end p 11
###begin title 12
Materials and methods
###end title 12
###begin p 13
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 248 256 <span type="species:ncbi:9606">children</span>
###xml 327 335 <span type="species:ncbi:9606">children</span>
Patient samples from bone marrow aspirates or peripheral blood were collected between 1999 and 2002 after informed consent had been obtained. Approximately 10 ml of peripheral blood or 1 ml of bone marrow was obtained from normal subjects and from children with B-ALL according to a procedure approved by the UFMC IRB and from children with T-ALL according to approved protocols. Samples were shipped overnight with the bone marrow samples diluted 1:2 in RPMI medium. To generate peripheral WBCs and nucleated bone marrow cells, red cells were lysed in 0.9% ammonium acetate according to standard procedures, and to generate peripheral blood lymphocytes, whole blood was applied to a Ficoll gradient as previously described. Some of the samples were cells isolated on a Ficoll gradient and frozen in 10% DMSO; these samples were washed once in PBS before further processing. As discussed later in Results, none of these isolation procedures altered the activation state of Ras.
###end p 13
###begin p 14
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
Samples from 23 patients were used: seven patients with AML, four patients with MPS (one osteomyelofibrosis (OMF), three CML), four patients with JMML, four patients with ALL and four with lymphoma including plasma cell leukemia. Except for the four patients with JMML, all patients were being treated in the Department of Medicine I at the University of Freiburg Medical Center.
###end p 14
###begin p 15
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 239 242 <span type="species:ncbi:10116">rat</span>
Because of problems associated with using 32PO4 to assess Ras activation, we used biochemical non-radioactive methods for measuring GTP and GDP bound to Ras family proteins as described before [25, 26]. Ras was immunoprecipitated with the rat monoclonal antibody Y13-259. Absolute amounts of GTP and GDP were measured in coupled enzymatic reactions. GTP was measured by converting it to ATP using the enzyme nucleoside diphosphate kinase (NDPK, Sigma St. Louis, MO) in the presence of ADP. The resulting ATP was measured by firefly luciferase (Calbiochem, San Diego, CA) in a photon counting luminometer. The firefly luciferase system is extremely sensitive, allowing detection of 1 fmol of GTP. To measure GDP, we converted it to GTP using the enzyme pyruvate kinase (PK, Sigma St. Louis, MO) with phosphoenolpyruvate serving as a source of high-energy phosphate.
###end p 15
###begin p 16
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 151 154 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 385 386 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 389 396 387 394 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 396 472 394 470 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Results of Ras activity determination and mutation analysis of control cells</p>
###xml 396 472 394 470 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Results of Ras activity determination and mutation analysis of control cells</p></caption>
###xml 472 481 470 479 <th xmlns:xlink="http://www.w3.org/1999/xlink">Cell line</th>
###xml 481 499 479 497 <th xmlns:xlink="http://www.w3.org/1999/xlink">GTP/(GTP+GDP) in %</th>
###xml 499 507 497 505 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sequence</th>
###xml 472 507 470 505 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Cell line</th><th>GTP/(GTP+GDP) in %</th><th>Sequence</th></tr>
###xml 472 507 470 505 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Cell line</th><th>GTP/(GTP+GDP) in %</th><th>Sequence</th></tr></thead>
###xml 507 512 505 510 <td xmlns:xlink="http://www.w3.org/1999/xlink">HL-60</td>
###xml 512 516 510 514 <td xmlns:xlink="http://www.w3.org/1999/xlink">20.9</td>
###xml 518 521 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 516 538 514 536 <td xmlns:xlink="http://www.w3.org/1999/xlink">N-<italic>ras</italic> codon 61 CAA-CTA</td>
###xml 507 538 505 536 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HL-60</td><td>20.9</td><td>N-<italic>ras</italic> codon 61 CAA-CTA</td></tr>
###xml 538 545 536 543 <td xmlns:xlink="http://www.w3.org/1999/xlink">3T3 V12</td>
###xml 545 549 543 547 <td xmlns:xlink="http://www.w3.org/1999/xlink">38.0</td>
###xml 551 554 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 549 558 547 556 <td xmlns:xlink="http://www.w3.org/1999/xlink">H-<italic>ras</italic> V12</td>
###xml 538 558 536 556 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>3T3 V12</td><td>38.0</td><td>H-<italic>ras</italic> V12</td></tr>
###xml 558 561 556 559 <td xmlns:xlink="http://www.w3.org/1999/xlink">697</td>
###xml 561 564 559 562 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.3</td>
###xml 564 566 562 564 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 558 566 556 564 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>697</td><td>6.3</td><td>WT</td></tr>
###xml 566 570 564 568 <td xmlns:xlink="http://www.w3.org/1999/xlink">U937</td>
###xml 570 573 568 571 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8</td>
###xml 573 575 571 573 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 566 575 564 573 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>U937</td><td>0.8</td><td>WT</td></tr>
###xml 575 581 573 579 <td xmlns:xlink="http://www.w3.org/1999/xlink">3T3 WT</td>
###xml 581 584 579 582 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.7</td>
###xml 584 586 582 584 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 575 586 573 584 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>3T3 WT</td><td>8.7</td><td>WT</td></tr>
###xml 589 590 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 586 590 584 588 <td xmlns:xlink="http://www.w3.org/1999/xlink">WBC<sup>a</sup></td>
###xml 590 593 588 591 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.2</td>
###xml 593 595 591 593 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 586 595 584 593 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>WBC<sup>a</sup></td><td>3.2</td><td>WT</td></tr>
###xml 507 595 505 593 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>HL-60</td><td>20.9</td><td>N-<italic>ras</italic> codon 61 CAA-CTA</td></tr><tr><td>3T3 V12</td><td>38.0</td><td>H-<italic>ras</italic> V12</td></tr><tr><td>697</td><td>6.3</td><td>WT</td></tr><tr><td>U937</td><td>0.8</td><td>WT</td></tr><tr><td>3T3 WT</td><td>8.7</td><td>WT</td></tr><tr><td>WBC<sup>a</sup></td><td>3.2</td><td>WT</td></tr></tbody>
###xml 472 595 470 593 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Cell line</th><th>GTP/(GTP+GDP) in %</th><th>Sequence</th></tr></thead><tbody><tr><td>HL-60</td><td>20.9</td><td>N-<italic>ras</italic> codon 61 CAA-CTA</td></tr><tr><td>3T3 V12</td><td>38.0</td><td>H-<italic>ras</italic> V12</td></tr><tr><td>697</td><td>6.3</td><td>WT</td></tr><tr><td>U937</td><td>0.8</td><td>WT</td></tr><tr><td>3T3 WT</td><td>8.7</td><td>WT</td></tr><tr><td>WBC<sup>a</sup></td><td>3.2</td><td>WT</td></tr></tbody></table>
###xml 595 596 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 595 630 593 628 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><sup>a</sup>WBCs isolated from a healthy donor</p>
###xml 771 774 769 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 849 852 847 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 630 1037 628 1035 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">GTP activation of Ras was measured in six different cell lines as positive controls, for which HL-60 cells (AML FAB M2) harbouring a known N-<italic>ras</italic> mutation were used as well as 3T3 transfected with a plasmid containing H-<italic>ras</italic> V12. Negative controls were U937 (myelogenous, WT), pre-B-ALL derived 697 cells as well as WT NIH3T3 cells. In addition WBCs from the peripheral blood of a healthy donor were analyzed.</p>
###xml 595 1037 593 1035 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><sup>a</sup>WBCs isolated from a healthy donor</p><p textid="19">GTP activation of Ras was measured in six different cell lines as positive controls, for which HL-60 cells (AML FAB M2) harbouring a known N-<italic>ras</italic> mutation were used as well as 3T3 transfected with a plasmid containing H-<italic>ras</italic> V12. Negative controls were U937 (myelogenous, WT), pre-B-ALL derived 697 cells as well as WT NIH3T3 cells. In addition WBCs from the peripheral blood of a healthy donor were analyzed.</p></table-wrap-foot>
###xml 389 1037 387 1035 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Results of Ras activity determination and mutation analysis of control cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cell line</th><th>GTP/(GTP+GDP) in %</th><th>Sequence</th></tr></thead><tbody><tr><td>HL-60</td><td>20.9</td><td>N-<italic>ras</italic> codon 61 CAA-CTA</td></tr><tr><td>3T3 V12</td><td>38.0</td><td>H-<italic>ras</italic> V12</td></tr><tr><td>697</td><td>6.3</td><td>WT</td></tr><tr><td>U937</td><td>0.8</td><td>WT</td></tr><tr><td>3T3 WT</td><td>8.7</td><td>WT</td></tr><tr><td>WBC<sup>a</sup></td><td>3.2</td><td>WT</td></tr></tbody></table><table-wrap-foot><p textid="18"><sup>a</sup>WBCs isolated from a healthy donor</p><p textid="19">GTP activation of Ras was measured in six different cell lines as positive controls, for which HL-60 cells (AML FAB M2) harbouring a known N-<italic>ras</italic> mutation were used as well as 3T3 transfected with a plasmid containing H-<italic>ras</italic> V12. Negative controls were U937 (myelogenous, WT), pre-B-ALL derived 697 cells as well as WT NIH3T3 cells. In addition WBCs from the peripheral blood of a healthy donor were analyzed.</p></table-wrap-foot></table-wrap>
###xml 230 236 <span type="species:ncbi:10090">Murine</span>
As positive controls, HL-60 cells (AML FAB M2) with a known N-ras mutation in codon 61 (CAA-->CTA) were used. As negative controls with known wildtype ras, the myelogenous cell line U937 and the pre-B-ALL cell line 697 were used. Murine 3T3 fibroblasts were used both as a negative and a positive control, the latter after being transfected with an activated H-Ras Val12 vector (Table 1). Table 1Results of Ras activity determination and mutation analysis of control cellsCell lineGTP/(GTP+GDP) in %SequenceHL-6020.9N-ras codon 61 CAA-CTA3T3 V1238.0H-ras V126976.3WTU9370.8WT3T3 WT8.7WTWBCa3.2WTaWBCs isolated from a healthy donorGTP activation of Ras was measured in six different cell lines as positive controls, for which HL-60 cells (AML FAB M2) harbouring a known N-ras mutation were used as well as 3T3 transfected with a plasmid containing H-ras V12. Negative controls were U937 (myelogenous, WT), pre-B-ALL derived 697 cells as well as WT NIH3T3 cells. In addition WBCs from the peripheral blood of a healthy donor were analyzed.
###end p 16
###begin p 17
Results of Ras activity determination and mutation analysis of control cells
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aWBCs isolated from a healthy donor
###end p 18
###begin p 19
###xml 141 144 141 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
GTP activation of Ras was measured in six different cell lines as positive controls, for which HL-60 cells (AML FAB M2) harbouring a known N-ras mutation were used as well as 3T3 transfected with a plasmid containing H-ras V12. Negative controls were U937 (myelogenous, WT), pre-B-ALL derived 697 cells as well as WT NIH3T3 cells. In addition WBCs from the peripheral blood of a healthy donor were analyzed.
###end p 19
###begin p 20
###xml 153 156 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 163 166 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
Genomic DNA was isolated using the commercially available "QIAamp DNA Blood Mini Kit" (QIAGEN GmbH, Hilden, Germany). Amplification was performed with K-ras and N-ras specific primers containing 5' universal M13 primer sequence attached, which were then used for genomic sequencing (ABI PRISM(R) BigDye Terminator Cycle Sequencing Kit and ABI310 Genetic Analyzer-System, Applied Biosystems, Foster City, USA)
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 0 117 0 117 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Frequency of N-ras and K-ras mutations in 23 patients with several hematological disorders and in one healthy control</p>
###xml 0 117 0 117 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Frequency of N-ras and K-ras mutations in 23 patients with several hematological disorders and in one healthy control</p></list-item>
###xml 0 117 0 117 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="23">Frequency of N-ras and K-ras mutations in 23 patients with several hematological disorders and in one healthy control</p></list-item></list>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Frequency of N-ras and K-ras mutations in 23 patients with several hematological disorders and in one healthy control
###end p 22
###begin p 23
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Frequency of N-ras and K-ras mutations in 23 patients with several hematological disorders and in one healthy control
###end p 23
###begin p 24
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 246 253 246 253 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 253 371 253 371 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphoma</p>
###xml 253 371 253 371 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphoma</p></caption>
###xml 371 380 371 380 <th xmlns:xlink="http://www.w3.org/1999/xlink">Patient #</th>
###xml 380 389 380 389 <th xmlns:xlink="http://www.w3.org/1999/xlink">Diagnosis</th>
###xml 389 389 389 389 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 389 389 389 389 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 389 389 389 389 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 389 389 389 389 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 389 389 389 389 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 389 389 389 389 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 371 389 371 389 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Patient #</th><th>Diagnosis</th><th/><th/><th/><th/><th/><th/></tr>
###xml 371 389 371 389 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Patient #</th><th>Diagnosis</th><th/><th/><th/><th/><th/><th/></tr></thead>
###xml 389 390 389 390 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 390 393 390 393 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 393 397 393 397 <td xmlns:xlink="http://www.w3.org/1999/xlink">19.8</td>
###xml 397 405 397 405 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mutation</td>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 405 410 405 410 <td xmlns:xlink="http://www.w3.org/1999/xlink">N-<italic>ras</italic></td>
###xml 410 416 410 416 <td xmlns:xlink="http://www.w3.org/1999/xlink">exon 1</td>
###xml 416 418 416 418 <td xmlns:xlink="http://www.w3.org/1999/xlink">12</td>
###xml 418 425 418 425 <td xmlns:xlink="http://www.w3.org/1999/xlink">GGT-TGT</td>
###xml 389 425 389 425 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>1</td><td>AML</td><td>19.8</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 1</td><td>12</td><td>GGT-TGT</td></tr>
###xml 425 426 425 426 <td xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 426 429 426 429 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 429 432 429 432 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.6</td>
###xml 432 434 432 434 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 434 434 434 434 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 434 434 434 434 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 434 434 434 434 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 434 434 434 434 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 425 434 425 434 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>2</td><td>AML</td><td>1.6</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 434 435 434 435 <td xmlns:xlink="http://www.w3.org/1999/xlink">3</td>
###xml 435 438 435 438 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 438 441 438 441 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.6</td>
###xml 441 443 441 443 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 443 443 443 443 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 443 443 443 443 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 443 443 443 443 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 443 443 443 443 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 434 443 434 443 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>3</td><td>AML</td><td>4.6</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 443 444 443 444 <td xmlns:xlink="http://www.w3.org/1999/xlink">4</td>
###xml 444 447 444 447 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 447 450 447 450 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.9</td>
###xml 450 452 450 452 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 452 452 452 452 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 452 452 452 452 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 452 452 452 452 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 452 452 452 452 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 443 452 443 452 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>4</td><td>AML</td><td>1.9</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 452 453 452 453 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 453 456 453 456 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 456 459 456 459 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.6</td>
###xml 459 461 459 461 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 461 461 461 461 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 461 461 461 461 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 461 461 461 461 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 461 461 461 461 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 452 461 452 461 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>AML</td><td>0.6</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 461 462 461 462 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 462 465 462 465 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 465 468 465 468 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.1</td>
###xml 468 470 468 470 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 470 470 470 470 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 470 470 470 470 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 470 470 470 470 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 470 470 470 470 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 461 470 461 470 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>AML</td><td>2.1</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 470 471 470 471 <td xmlns:xlink="http://www.w3.org/1999/xlink">7</td>
###xml 471 474 471 474 <td xmlns:xlink="http://www.w3.org/1999/xlink">AML</td>
###xml 474 477 474 477 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.2</td>
###xml 477 485 477 485 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mutation</td>
###xml 487 490 487 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 485 490 485 490 <td xmlns:xlink="http://www.w3.org/1999/xlink">N-<italic>ras</italic></td>
###xml 490 496 490 496 <td xmlns:xlink="http://www.w3.org/1999/xlink">exon 2</td>
###xml 496 498 496 498 <td xmlns:xlink="http://www.w3.org/1999/xlink">61</td>
###xml 498 505 498 505 <td xmlns:xlink="http://www.w3.org/1999/xlink">CAA-AAA</td>
###xml 470 505 470 505 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>7</td><td>AML</td><td>1.2</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 2</td><td>61</td><td>CAA-AAA</td></tr>
###xml 505 506 505 506 <td xmlns:xlink="http://www.w3.org/1999/xlink">8</td>
###xml 506 509 506 509 <td xmlns:xlink="http://www.w3.org/1999/xlink">ALL</td>
###xml 509 512 509 512 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.5</td>
###xml 512 514 512 514 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 514 514 514 514 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 514 514 514 514 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 514 514 514 514 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 514 514 514 514 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 505 514 505 514 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>8</td><td>ALL</td><td>2.5</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 514 515 514 515 <td xmlns:xlink="http://www.w3.org/1999/xlink">9</td>
###xml 515 518 515 518 <td xmlns:xlink="http://www.w3.org/1999/xlink">ALL</td>
###xml 518 521 518 521 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.7</td>
###xml 521 523 521 523 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 523 523 523 523 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 523 523 523 523 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 523 523 523 523 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 523 523 523 523 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 514 523 514 523 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>9</td><td>ALL</td><td>2.7</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 523 525 523 525 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 525 528 525 528 <td xmlns:xlink="http://www.w3.org/1999/xlink">ALL</td>
###xml 528 531 528 531 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1</td>
###xml 531 533 531 533 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 533 533 533 533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 533 533 533 533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 533 533 533 533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 533 533 533 533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 523 533 523 533 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>10</td><td>ALL</td><td>5.1</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 533 535 533 535 <td xmlns:xlink="http://www.w3.org/1999/xlink">11</td>
###xml 535 538 535 538 <td xmlns:xlink="http://www.w3.org/1999/xlink">ALL</td>
###xml 538 541 538 541 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.5</td>
###xml 541 543 541 543 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 543 543 543 543 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 543 543 543 543 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 543 543 543 543 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 543 543 543 543 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 533 543 533 543 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>11</td><td>ALL</td><td>1.5</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 543 545 543 545 <td xmlns:xlink="http://www.w3.org/1999/xlink">12</td>
###xml 545 548 545 548 <td xmlns:xlink="http://www.w3.org/1999/xlink">CML</td>
###xml 548 551 548 551 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.4</td>
###xml 551 553 551 553 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 553 553 553 553 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 553 553 553 553 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 553 553 553 553 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 553 553 553 553 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 543 553 543 553 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>12</td><td>CML</td><td>2.4</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 553 555 553 555 <td xmlns:xlink="http://www.w3.org/1999/xlink">13</td>
###xml 555 558 555 558 <td xmlns:xlink="http://www.w3.org/1999/xlink">CML</td>
###xml 558 561 558 561 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.9</td>
###xml 561 563 561 563 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 563 563 563 563 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 563 563 563 563 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 563 563 563 563 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 563 563 563 563 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 553 563 553 563 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>13</td><td>CML</td><td>5.9</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 563 565 563 565 <td xmlns:xlink="http://www.w3.org/1999/xlink">14</td>
###xml 565 573 565 573 <td xmlns:xlink="http://www.w3.org/1999/xlink">lymphoma</td>
###xml 573 577 573 577 <td xmlns:xlink="http://www.w3.org/1999/xlink">15.4</td>
###xml 577 585 577 585 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mutation</td>
###xml 587 590 587 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 585 590 585 590 <td xmlns:xlink="http://www.w3.org/1999/xlink">N-<italic>ras</italic></td>
###xml 590 595 590 595 <td xmlns:xlink="http://www.w3.org/1999/xlink">exon1</td>
###xml 595 597 595 597 <td xmlns:xlink="http://www.w3.org/1999/xlink">12</td>
###xml 597 604 597 604 <td xmlns:xlink="http://www.w3.org/1999/xlink">GGT-GAT</td>
###xml 563 604 563 604 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>14</td><td>lymphoma</td><td>15.4</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon1</td><td>12</td><td>GGT-GAT</td></tr>
###xml 604 606 604 606 <td xmlns:xlink="http://www.w3.org/1999/xlink">15</td>
###xml 606 610 606 610 <td xmlns:xlink="http://www.w3.org/1999/xlink">JMML</td>
###xml 610 614 610 614 <td xmlns:xlink="http://www.w3.org/1999/xlink">38.6</td>
###xml 614 616 614 616 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 616 616 616 616 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 616 616 616 616 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 616 616 616 616 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 616 616 616 616 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 604 616 604 616 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>15</td><td>JMML</td><td>38.6</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 616 618 616 618 <td xmlns:xlink="http://www.w3.org/1999/xlink">16</td>
###xml 618 622 618 622 <td xmlns:xlink="http://www.w3.org/1999/xlink">JMML</td>
###xml 622 626 622 626 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.7</td>
###xml 626 628 626 628 <td xmlns:xlink="http://www.w3.org/1999/xlink">Nd</td>
###xml 628 628 628 628 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 628 628 628 628 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 628 628 628 628 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 628 628 628 628 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 616 628 616 628 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>16</td><td>JMML</td><td>11.7</td><td>Nd</td><td/><td/><td/><td/></tr>
###xml 628 630 628 630 <td xmlns:xlink="http://www.w3.org/1999/xlink">17</td>
###xml 630 634 630 634 <td xmlns:xlink="http://www.w3.org/1999/xlink">JMML</td>
###xml 634 638 634 638 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.4</td>
###xml 638 646 638 646 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mutation</td>
###xml 646 646 646 646 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 646 646 646 646 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 646 648 646 648 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 648 648 648 648 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 628 648 628 648 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>17</td><td>JMML</td><td>16.4</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr>
###xml 648 650 648 650 <td xmlns:xlink="http://www.w3.org/1999/xlink">18</td>
###xml 650 654 650 654 <td xmlns:xlink="http://www.w3.org/1999/xlink">JMML</td>
###xml 654 657 654 657 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.1</td>
###xml 657 665 657 665 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mutation</td>
###xml 665 665 665 665 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 665 665 665 665 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 665 667 665 667 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 667 667 667 667 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 648 667 648 667 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>18</td><td>JMML</td><td>1.1</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr>
###xml 667 669 667 669 <td xmlns:xlink="http://www.w3.org/1999/xlink">19</td>
###xml 669 671 669 671 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 671 675 671 675 <td xmlns:xlink="http://www.w3.org/1999/xlink">32.7</td>
###xml 675 677 675 677 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 677 677 677 677 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 677 677 677 677 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 677 677 677 677 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 677 677 677 677 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 667 677 667 677 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>19</td><td>nd</td><td>32.7</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 677 679 677 679 <td xmlns:xlink="http://www.w3.org/1999/xlink">20</td>
###xml 679 681 679 681 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 681 684 681 684 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.7</td>
###xml 684 686 684 686 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 686 686 686 686 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 686 686 686 686 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 686 686 686 686 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 686 686 686 686 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 677 686 677 686 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>20</td><td>nd</td><td>1.7</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 686 688 686 688 <td xmlns:xlink="http://www.w3.org/1999/xlink">21</td>
###xml 688 690 688 690 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 690 693 690 693 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.3</td>
###xml 693 695 693 695 <td xmlns:xlink="http://www.w3.org/1999/xlink">WT</td>
###xml 695 695 695 695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 695 695 695 695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 695 695 695 695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 695 695 695 695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 686 695 686 695 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>21</td><td>nd</td><td>7.3</td><td>WT</td><td/><td/><td/><td/></tr>
###xml 695 697 695 697 <td xmlns:xlink="http://www.w3.org/1999/xlink">22</td>
###xml 697 699 697 699 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 699 702 699 702 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.9</td>
###xml 702 704 702 704 <td xmlns:xlink="http://www.w3.org/1999/xlink">Nd</td>
###xml 704 704 704 704 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 704 704 704 704 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 704 704 704 704 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 704 704 704 704 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 695 704 695 704 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>22</td><td>nd</td><td>2.9</td><td>Nd</td><td/><td/><td/><td/></tr>
###xml 704 706 704 706 <td xmlns:xlink="http://www.w3.org/1999/xlink">23</td>
###xml 706 708 706 708 <td xmlns:xlink="http://www.w3.org/1999/xlink">nd</td>
###xml 708 711 708 711 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.9</td>
###xml 711 713 711 713 <td xmlns:xlink="http://www.w3.org/1999/xlink">Nd</td>
###xml 713 713 713 713 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 713 713 713 713 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 713 713 713 713 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 713 713 713 713 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 704 713 704 713 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>23</td><td>nd</td><td>4.9</td><td>Nd</td><td/><td/><td/><td/></tr>
###xml 389 713 389 713 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>1</td><td>AML</td><td>19.8</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 1</td><td>12</td><td>GGT-TGT</td></tr><tr><td>2</td><td>AML</td><td>1.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>3</td><td>AML</td><td>4.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>4</td><td>AML</td><td>1.9</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>5</td><td>AML</td><td>0.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>6</td><td>AML</td><td>2.1</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>7</td><td>AML</td><td>1.2</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 2</td><td>61</td><td>CAA-AAA</td></tr><tr><td>8</td><td>ALL</td><td>2.5</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>9</td><td>ALL</td><td>2.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>10</td><td>ALL</td><td>5.1</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>11</td><td>ALL</td><td>1.5</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>12</td><td>CML</td><td>2.4</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>13</td><td>CML</td><td>5.9</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>14</td><td>lymphoma</td><td>15.4</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon1</td><td>12</td><td>GGT-GAT</td></tr><tr><td>15</td><td>JMML</td><td>38.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>16</td><td>JMML</td><td>11.7</td><td>Nd</td><td/><td/><td/><td/></tr><tr><td>17</td><td>JMML</td><td>16.4</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr><tr><td>18</td><td>JMML</td><td>1.1</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr><tr><td>19</td><td>nd</td><td>32.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>20</td><td>nd</td><td>1.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>21</td><td>nd</td><td>7.3</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>22</td><td>nd</td><td>2.9</td><td>Nd</td><td/><td/><td/><td/></tr><tr><td>23</td><td>nd</td><td>4.9</td><td>Nd</td><td/><td/><td/><td/></tr></tbody>
###xml 371 713 371 713 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Patient #</th><th>Diagnosis</th><th/><th/><th/><th/><th/><th/></tr></thead><tbody><tr><td>1</td><td>AML</td><td>19.8</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 1</td><td>12</td><td>GGT-TGT</td></tr><tr><td>2</td><td>AML</td><td>1.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>3</td><td>AML</td><td>4.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>4</td><td>AML</td><td>1.9</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>5</td><td>AML</td><td>0.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>6</td><td>AML</td><td>2.1</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>7</td><td>AML</td><td>1.2</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 2</td><td>61</td><td>CAA-AAA</td></tr><tr><td>8</td><td>ALL</td><td>2.5</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>9</td><td>ALL</td><td>2.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>10</td><td>ALL</td><td>5.1</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>11</td><td>ALL</td><td>1.5</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>12</td><td>CML</td><td>2.4</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>13</td><td>CML</td><td>5.9</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>14</td><td>lymphoma</td><td>15.4</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon1</td><td>12</td><td>GGT-GAT</td></tr><tr><td>15</td><td>JMML</td><td>38.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>16</td><td>JMML</td><td>11.7</td><td>Nd</td><td/><td/><td/><td/></tr><tr><td>17</td><td>JMML</td><td>16.4</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr><tr><td>18</td><td>JMML</td><td>1.1</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr><tr><td>19</td><td>nd</td><td>32.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>20</td><td>nd</td><td>1.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>21</td><td>nd</td><td>7.3</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>22</td><td>nd</td><td>2.9</td><td>Nd</td><td/><td/><td/><td/></tr><tr><td>23</td><td>nd</td><td>4.9</td><td>Nd</td><td/><td/><td/><td/></tr></tbody></table>
###xml 739 748 739 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n-, k-ras</italic>
###xml 713 1101 713 1101 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Overall, the sequences of <italic>n-, k-ras</italic> were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).</p>
###xml 713 1101 713 1101 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Overall, the sequences of <italic>n-, k-ras</italic> were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).</p></table-wrap-foot>
###xml 246 1101 246 1101 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="25">Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphoma</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient #</th><th>Diagnosis</th><th/><th/><th/><th/><th/><th/></tr></thead><tbody><tr><td>1</td><td>AML</td><td>19.8</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 1</td><td>12</td><td>GGT-TGT</td></tr><tr><td>2</td><td>AML</td><td>1.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>3</td><td>AML</td><td>4.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>4</td><td>AML</td><td>1.9</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>5</td><td>AML</td><td>0.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>6</td><td>AML</td><td>2.1</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>7</td><td>AML</td><td>1.2</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon 2</td><td>61</td><td>CAA-AAA</td></tr><tr><td>8</td><td>ALL</td><td>2.5</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>9</td><td>ALL</td><td>2.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>10</td><td>ALL</td><td>5.1</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>11</td><td>ALL</td><td>1.5</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>12</td><td>CML</td><td>2.4</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>13</td><td>CML</td><td>5.9</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>14</td><td>lymphoma</td><td>15.4</td><td>Mutation</td><td>N-<italic>ras</italic></td><td>exon1</td><td>12</td><td>GGT-GAT</td></tr><tr><td>15</td><td>JMML</td><td>38.6</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>16</td><td>JMML</td><td>11.7</td><td>Nd</td><td/><td/><td/><td/></tr><tr><td>17</td><td>JMML</td><td>16.4</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr><tr><td>18</td><td>JMML</td><td>1.1</td><td>Mutation</td><td/><td/><td>nd</td><td/></tr><tr><td>19</td><td>nd</td><td>32.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>20</td><td>nd</td><td>1.7</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>21</td><td>nd</td><td>7.3</td><td>WT</td><td/><td/><td/><td/></tr><tr><td>22</td><td>nd</td><td>2.9</td><td>Nd</td><td/><td/><td/><td/></tr><tr><td>23</td><td>nd</td><td>4.9</td><td>Nd</td><td/><td/><td/><td/></tr></tbody></table><table-wrap-foot><p textid="26">Overall, the sequences of <italic>n-, k-ras</italic> were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).</p></table-wrap-foot></table-wrap>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 771 778 <span type="species:ncbi:9606">patient</span>
###xml 792 799 <span type="species:ncbi:9606">patient</span>
###xml 958 966 <span type="species:ncbi:9606">patients</span>
Table 2 shows results of Ras activation in peripheral blood and bone marrow WBCs from a total of 23 patients: seven with AML, four with ALL, two with CML, four with JMML and one with lymphoma. No diagnosis could be given to five of the patients. Table 2Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphomaPatient #Diagnosis1AML19.8MutationN-rasexon 112GGT-TGT2AML1.6WT3AML4.6WT4AML1.9WT5AML0.6WT6AML2.1WT7AML1.2MutationN-rasexon 261CAA-AAA8ALL2.5WT9ALL2.7WT10ALL5.1WT11ALL1.5WT12CML2.4WT13CML5.9WT14lymphoma15.4MutationN-rasexon112GGT-GAT15JMML38.6WT16JMML11.7Nd17JMML16.4Mutationnd18JMML1.1Mutationnd19nd32.7WT20nd1.7WT21nd7.3WT22nd2.9Nd23nd4.9NdOverall, the sequences of n-, k-ras were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).
###end p 24
###begin p 25
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphoma
###end p 25
###begin p 26
###xml 26 35 26 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n-, k-ras</italic>
###xml 58 65 <span type="species:ncbi:9606">patient</span>
###xml 79 86 <span type="species:ncbi:9606">patient</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
Overall, the sequences of n-, k-ras were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).
###end p 26
###begin p 27
Mutation analysis confirmed mutations in the positive controls, and showed mutations in two of the seven AML samples (29%), one in codon 12 (exon1) and one in codon 61 (exon2). The latter data are consistent with the mutation frequencies reported in the literature. Our results are also in accordance with recent data indicating that the frequency of Ras mutations in AML and MDS has been overestimated in the past (M. Lubbert, personal communication).
###end p 27
###begin p 28
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 312 315 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 342 345 342 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras</italic>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 509 655 509 655 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Frequency of Ras activation in 23 patients with several hematological disorders and in one healthy control (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) and in six cell lines (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>)</p>
###xml 509 655 509 655 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Frequency of Ras activation in 23 patients with several hematological disorders and in one healthy control (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) and in six cell lines (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>)</p></list-item>
###xml 509 655 509 655 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="29">Frequency of Ras activation in 23 patients with several hematological disorders and in one healthy control (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) and in six cell lines (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>)</p></list-item></list>
###xml 655 661 655 661 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 930 934 930 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bars</italic>
###xml 1077 1078 1077 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1088 1089 1088 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 661 1106 661 1106 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Ras Activation in 12 different determinations (dots) of Ras activation [GTP/(GDT+GTP)%] of control cells lines according to their mutational status. Samples with known WT sequences are shown separate from samples with known activating mutation. The 95% CI are shown by <italic>bars</italic>. Average ras activation in WT versus mutation samples is 4.75% (0.8&#8211;8.7%) vs. 23.06% (12.7&#8211;38%) respectively. This difference is significant (<italic>p</italic>&#8201;=&#8201;0.006; <italic>t</italic>-test, ungrouped)</p>
###xml 661 1106 661 1106 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Ras Activation in 12 different determinations (dots) of Ras activation [GTP/(GDT+GTP)%] of control cells lines according to their mutational status. Samples with known WT sequences are shown separate from samples with known activating mutation. The 95% CI are shown by <italic>bars</italic>. Average ras activation in WT versus mutation samples is 4.75% (0.8&#8211;8.7%) vs. 23.06% (12.7&#8211;38%) respectively. This difference is significant (<italic>p</italic>&#8201;=&#8201;0.006; <italic>t</italic>-test, ungrouped)</p></caption>
###xml 1106 1106 1106 1106 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2008_593_Fig1_HTML" id="MO1"/>
###xml 655 1106 655 1106 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="30">Ras Activation in 12 different determinations (dots) of Ras activation [GTP/(GDT+GTP)%] of control cells lines according to their mutational status. Samples with known WT sequences are shown separate from samples with known activating mutation. The 95% CI are shown by <italic>bars</italic>. Average ras activation in WT versus mutation samples is 4.75% (0.8&#8211;8.7%) vs. 23.06% (12.7&#8211;38%) respectively. This difference is significant (<italic>p</italic>&#8201;=&#8201;0.006; <italic>t</italic>-test, ungrouped)</p></caption><graphic position="anchor" xlink:href="277_2008_593_Fig1_HTML" id="MO1"/></fig>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 472 479 <span type="species:ncbi:9606">patient</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
In the samples from patients with MPS again no mutation of Ras could be detected, a finding which has been previously explained by constitutive Ras activation via the uncontrolled Bcr-Abl signal upstream of Ras [31]. None of the four ALL samples showed a mutation. This is compatible with the lower frequency of ras mutations in this entity. Ras mutations were also found in two of the JMML samples. A N-Ras mutation has been found in codon 12 (exon 1) of a sample from a patient with a plasma cell leukemia. Frequency of Ras activation in 23 patients with several hematological disorders and in one healthy control (Fig. 2) and in six cell lines (Fig. 1)Fig. 1Ras Activation in 12 different determinations (dots) of Ras activation [GTP/(GDT+GTP)%] of control cells lines according to their mutational status. Samples with known WT sequences are shown separate from samples with known activating mutation. The 95% CI are shown by bars. Average ras activation in WT versus mutation samples is 4.75% (0.8-8.7%) vs. 23.06% (12.7-38%) respectively. This difference is significant (p = 0.006; t-test, ungrouped)
###end p 28
###begin p 29
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Frequency of Ras activation in 23 patients with several hematological disorders and in one healthy control (Fig. 2) and in six cell lines (Fig. 1)
###end p 29
###begin p 30
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bars</italic>
###xml 416 417 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Ras Activation in 12 different determinations (dots) of Ras activation [GTP/(GDT+GTP)%] of control cells lines according to their mutational status. Samples with known WT sequences are shown separate from samples with known activating mutation. The 95% CI are shown by bars. Average ras activation in WT versus mutation samples is 4.75% (0.8-8.7%) vs. 23.06% (12.7-38%) respectively. This difference is significant (p = 0.006; t-test, ungrouped)
###end p 30
###begin p 31
###xml 414 417 414 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
Recent mathematical models of the Ras signaling pathway supported by experimental observations have underlined the function of Ras as a 'molecular switch' in signal transduction. Given four hypothetical disruptions in Ras signaling-GAP insensitivity, reduced GTPase activity, increased effector affinity and competitive inhibition of Ras-GAP by Ras RasVal12-it was hypothesized that cells harboring a heterozygous ras mutation resulting in a GAP-insensitive RasVal12 show an hypothetical activation (total Ras bound GTP) of approximately 28%. By contrast, wildtype (WT cells) should show an activation of approximately 5% [27].
###end p 31
###begin p 32
###xml 8 9 8 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
In Fig. 1, Ras activation from 12 different determinations [GTP/(GDT+GTP)%] were grouped according to their mutational status. The 95% CIs are represented by bars. Average Ras activation in WT was 4.75% (0.8-8.7%) vs. 23.06% (12.7-38%) respectively. This difference proved significant (p = 0.006; t-test, ungrouped).
###end p 32
###begin p 33
###xml 8 9 8 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 433 439 433 439 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 522 526 522 526 <bold xmlns:xlink="http://www.w3.org/1999/xlink">bold</bold>
###xml 870 883 870 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical bars</italic>
###xml 439 883 439 883 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Ras activation of patient samples according to their mutational status. Numbers in <bold>bold</bold> represent average levels of Ras activation. A patient sample was considered to have activated Ras if activation level was within the 95% confidence interval (CI) of the positive controls, and negative for Ras activation if it was within the 95% CI of the negative controls. The 95% CIs of the positive and negative controls are represented by <italic>vertical bars</italic></p>
###xml 439 883 439 883 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Ras activation of patient samples according to their mutational status. Numbers in <bold>bold</bold> represent average levels of Ras activation. A patient sample was considered to have activated Ras if activation level was within the 95% confidence interval (CI) of the positive controls, and negative for Ras activation if it was within the 95% CI of the negative controls. The 95% CIs of the positive and negative controls are represented by <italic>vertical bars</italic></p></caption>
###xml 883 883 883 883 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2008_593_Fig2_HTML" id="MO2"/>
###xml 433 883 433 883 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="34">Ras activation of patient samples according to their mutational status. Numbers in <bold>bold</bold> represent average levels of Ras activation. A patient sample was considered to have activated Ras if activation level was within the 95% confidence interval (CI) of the positive controls, and negative for Ras activation if it was within the 95% CI of the negative controls. The 95% CIs of the positive and negative controls are represented by <italic>vertical bars</italic></p></caption><graphic position="anchor" xlink:href="277_2008_593_Fig2_HTML" id="MO2"/></fig>
###xml 29 36 <span type="species:ncbi:9606">patient</span>
###xml 92 99 <span type="species:ncbi:9606">Patient</span>
###xml 164 171 <span type="species:ncbi:9606">patient</span>
###xml 457 464 <span type="species:ncbi:9606">patient</span>
###xml 573 580 <span type="species:ncbi:9606">patient</span>
In Fig. 2, Ras activation of patient samples is shown according to their mutational status. Patient samples (n = 23) are separated by their hematological entity. A patient sample was considered to contain activated Ras if the activation level was within the 95% CI of the positive controls, and negative if it was within the 95% CI of the negative controls. Both 95% CIs of negative and positive control cells are indicated by bars. Fig. 2Ras activation of patient samples according to their mutational status. Numbers in bold represent average levels of Ras activation. A patient sample was considered to have activated Ras if activation level was within the 95% confidence interval (CI) of the positive controls, and negative for Ras activation if it was within the 95% CI of the negative controls. The 95% CIs of the positive and negative controls are represented by vertical bars
###end p 33
###begin p 34
###xml 83 87 83 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">bold</bold>
###xml 431 444 431 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical bars</italic>
###xml 18 25 <span type="species:ncbi:9606">patient</span>
###xml 134 141 <span type="species:ncbi:9606">patient</span>
Ras activation of patient samples according to their mutational status. Numbers in bold represent average levels of Ras activation. A patient sample was considered to have activated Ras if activation level was within the 95% confidence interval (CI) of the positive controls, and negative for Ras activation if it was within the 95% CI of the negative controls. The 95% CIs of the positive and negative controls are represented by vertical bars
###end p 34
###begin p 35
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 166 169 166 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 334 397 334 397 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Discrepancy between Ras activation and ras activating mutations</p>
###xml 334 397 334 397 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Discrepancy between Ras activation and ras activating mutations</p></list-item>
###xml 334 397 334 397 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="36">Discrepancy between Ras activation and ras activating mutations</p></list-item></list>
###xml 26 33 <span type="species:ncbi:9606">patient</span>
###xml 145 152 <span type="species:ncbi:9606">patient</span>
The average activation of patient samples with proven ras mutations (n = 5) was 10.8% (1.1-19.8%; 95% CI, 0.333-23.3). The average activation of patient samples with ras WT sequence was 7.41% (0.6-38.6%; 95% CI, 1.32-13.44). Since the 95% CIs overlap in this analysis, the difference is not significant (p = 0.565, t-test ungrouped). Discrepancy between Ras activation and ras activating mutations
###end p 35
###begin p 36
Discrepancy between Ras activation and ras activating mutations
###end p 36
###begin p 37
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
One of the two samples with activating Ras from patients with AML, the a N-ras mutation of codon 61 in exon 2 resulting in a CAA-AAA sequence, did not show a higher percentage of GTP-Ras which would be indicative of an activation of the protein, whereas the N-ras mutation in codon 12 of Exon resulting in a GGT-TGT sequence was correlated with a GTP/GTP+GDP ratio of 19.8%. In the samples from patients with JMML, one sample had no increased Ras-GTP in spite of an activating mutation. One wildtype sample showed a Ras-GTP percentage of 38.6% without an activating Ras-mutation.
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
The frequencies of mutations found in our study for different forms of hematological malignancies do not reach significance levels due to the low number of samples, but in general they reflect the tendencies found in previous reports [35].
###end p 39
###begin p 40
###xml 63 66 63 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 736 739 736 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 751 754 751 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1044 1047 1044 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 468 475 <span type="species:ncbi:9606">patient</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 865 872 <span type="species:ncbi:9606">patient</span>
###xml 1010 1017 <span type="species:ncbi:9606">patient</span>
###xml 1111 1118 <span type="species:ncbi:9606">patient</span>
We showed that cell lines with known constitutively activating ras mutations had significantly higher levels of Ras-GTP (mean activation 23.1%, p = 0.006) than did cell lines with WT-Ras (mean activation 4.8%). These data show the high degree of selectivity of the assay in distinguishing between cells with activated and non-activated Ras and are consistent with hypothetical and observed activations [28]. Determination of a threshold for positive Ras activation in patient samples is difficult. Given the aspect of Ras functioning as 'molecular switch' and taking into account the expected heterogenity of patients' primary cells (Ras isoforms, clonality, etc.) we established two ranges (95% CIs) of cell populations with either WT ras or mutated ras in order to be able to classify patients' values as activated or not activated in the setting of our assay. A patient sample was considered to have an activated Ras if the activation level was within the 95% CI of the positive controls. Three of the five patient samples (60%) with proven ras mutations belong in this category. On the other hand, 12 of 14 patient samples (approximately 86%) with wildtype sequence are within the 95% CI of the negative controls.
###end p 40
###begin p 41
###xml 97 104 <span type="species:ncbi:9606">patient</span>
The lack of intermediate values reflects the function of Ras as a 'molecular switch'. Therefore, patient samples with increased Ras activation lacking a mutational activation are of interest for further analysis of the Ras signal transduction cascade, since various up- and downstream effectors contribute to Ras activation.
###end p 41
###begin p 42
###xml 349 352 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
Ras mutations were found in hematological neoplasia known to have mutated Ras: two of six AML cases, one of two plasma cell leukemias (PCL), and two of four JMML cases. In two of the five patients with Ras mutations, Ras showed increased activation. However, one AML and one JMML sample showed noticeably low levels of activation though harboring a ras mutation.
###end p 42
###begin p 43
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
In addition to technical difficulties with the applied highly sensitive enzyme-based method, heterogeneity of the underlying patients' samples has to be taken into account. In further studies, the issue of clonality of samples could be overcome by pre-sorting cells, e.g., by flourescence activated cell sorter (FACS). Another explanation might be additional compensatory factors bypassing Ras such as, for example, by GAP [29] regulation or compensatory up-regulation of WT-Ras.
###end p 43
###begin p 44
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 7 14 <span type="species:ncbi:9606">patient</span>
In the patient sample with a Ras activation of 32.7% but no underlying mutation, the diagnosis was pre-B-ALL. In this context, CD40-stimulated Ras activation in the early developmental stages of B-cells has been described [30].
###end p 44
###begin p 45
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
Assessing Ras quantitatively in hematopoietic neoplasia may provide a basis for understanding the role of Ras in various signal transduction pathways and may provide new routes toward targeted treatment strategies. The most promising category influencing Ras signalling is farnesyltransferase inhibitors (FTIs), which inhibit the attachment of the farnesyl moiety to the Ras protein [32, 33]. In addition, drugs which interfere with the interaction of the farnesyl group with the cell membrane, such as farnesyl thiosalicylic acid, also influence the activity of Ras on a protein level [34].
###end p 45
###begin title 46
Electronic supplementary material
###end title 46
###begin p 47
Below is the link to the electronic supplementary material.
###end p 47
###begin p 48
Primers used for mutation analysis (DOC 24.5 KB)
###end p 48
###begin title 49
Acknowledgment
###end title 49
###begin p 50
###xml 241 249 <span type="species:ncbi:9606">patients</span>
This work was supported by the Deutsche Krebshilfe Grant 10-728 sche2. We thank Prof. Dr. C. Niemeyer, Department of Pediatric Hematology and Oncology, Centre for Pediatric and Adolescent Medicine Freiburg, for providing the samples of JMML patients.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
###xml 46 51 <span type="species:ncbi:9606">human</span>
Analysis of the transforming potential of the human H-ras gene by random mutagenesis
###end article-title 52
###begin article-title 53
N-ras mutations in 43 Chinese cases of acute myeloid leukemia
###end article-title 53
###begin article-title 54
Analysis of ras gene mutations in childhood myeloid leukaemia
###end article-title 54
###begin article-title 55
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
###end article-title 55
###begin article-title 56
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
###end article-title 56
###begin article-title 57
Oncoprotein networks
###end article-title 57
###begin article-title 58
###xml 16 21 <span type="species:ncbi:9606">human</span>
Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia
###end article-title 58
###begin article-title 59
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
###end article-title 59
###begin article-title 60
Growth and differentiation signals regulated by the M-CSF receptor
###end article-title 60
###begin article-title 61
Negative regulation of pl20GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth
###end article-title 61
###begin article-title 62
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
###end article-title 62
###begin article-title 63
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
###end article-title 63
###begin article-title 64
###xml 69 74 <span type="species:ncbi:9606">human</span>
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
###end article-title 64
###begin article-title 65
Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions
###end article-title 65
###begin article-title 66
Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma
###end article-title 66
###begin article-title 67
The neurofibromatosis type 1 gene encodes a protein related to GAP
###end article-title 67
###begin article-title 68
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
###end article-title 68
###begin article-title 69
###xml 66 74 <span type="species:ncbi:9606">children</span>
Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders
###end article-title 69
###begin article-title 70
Mutations of the N-ras gene in juvenile chronic myelogenous leukemia
###end article-title 70
###begin article-title 71
Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras
###end article-title 71
###begin article-title 72
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
###end article-title 72
###begin article-title 73
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
###end article-title 73
###begin article-title 74
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
###end article-title 74
###begin article-title 75
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
###end article-title 75
###begin article-title 76
Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: Comparison of parental and ras-overproducing NIH 3T3 fibroblasts
###end article-title 76
###begin article-title 77
Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia
###end article-title 77
###begin article-title 78
Network analysis of oncogenic Ras activation in cancer
###end article-title 78
###begin article-title 79
###xml 48 53 <span type="species:ncbi:9606">human</span>
Expression of normal and mutant ras proteins in human acute leukemia
###end article-title 79
###begin article-title 80
GAPs in growth factor signalling
###end article-title 80
###begin article-title 81
Activation of the Ras signaling pathway by the CD40 receptor
###end article-title 81
###begin article-title 82
Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia
###end article-title 82
###begin article-title 83
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
###end article-title 83
###begin article-title 84
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
###end article-title 84
###begin article-title 85
A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells
###end article-title 85
###begin article-title 86
The role of Ras and other low-molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation
###end article-title 86
###begin p 87
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 87
###begin p 88
The online version of this article (doi:10.1007/s00277-008-0593-6) contains supplementary material, which is available to authorized users.
###end p 88

